# PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

> **NCT00276523** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** PEG-interferon alfa-2b
- **PROCEDURE:** Conventional surgery
- **PROCEDURE:** Neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00276523
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2012-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276523, "PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00276523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*